Louis Scafuri

Founded in 2014, ZALEA, LLC (Irvine, CA) is the fastest growing online global community that aggregates, individualizes and delivers trusted content, reviews and the latest news and information in the aesthetic industry. ZALEA is keeping patients engaged through company initiated incentives, expert procedure reviews and by bringing knowledgeable consumers to qualified providers.

Syneron Medical Ltd. (NASDAQ: ELOS) is the leading global aesthetic device company with a comprehensive product portfolio and a global distribution footprint. The Company's technology enables physicians to provide advanced solutions for a broad range of medical-aesthetic applications. The Company sells its products under two distinct brands: Syneron and Candela. Founded in 2000, the corporate, R&D, and manufacturing headquarters for Syneron Medical Ltd. are located in Israel. Syneron also has R&D and manufacturing operations in the US. The Company markets, services, and supports its products in 90 countries. It has eleven global locations. Additional information can be found at http://syneron-candela.com/na.

Founder, ENTREPRENEUR & ANGEL INVESTOR and CEO 2002 - 2009 · about 7 years Founded a portfolio of companies including: • PRIME AESTHETIC was aesthetic product company with novel business plan positioned to disrupt current market dynamics of rapidly growing aesthetic device industry. Founder, CEO (Acquired by Syneron February 2009.) • LIGAND an early stage medical device company with patented analytical methodology for neonatal neural function screening. • TTL BEACON VENTURES an early stage biotech development company with a patented OTC treatment for rosacea.

Responsible for leadership of Company’s global operations. • Led company‘s effort to acquire largest competitor Coherent Medical Systems to become undisputed market leader in medical lasers (Lumens Medical). • Top line increased from $140M to $400M. • Increased EPS from a net loss of ($4.50/share) to $2.50/share. • Investor relations activities resulting in share price increase over of tenfold $2.00 (April 1999) to $32.00 (August 2001) regaining analyst coverage and market confidence.

Marquette Medical Systems was recognized as the innovator in diagnostic cardiology and patient monitoring systems until it was acquired by GE Healthcare in November 1998 for $886M. Served as COO and President with responsibility for company-wide global operations; • Primary role in investor relations and corporate strategy. • Responsibilities also included general management of cardiology business strategic direction; P&L of cardiology business groups across four global locations. • Played key role in GE Medical Systems merger with share value increase from $12.00/share to $45.00/share. • Achieved record operating results.